{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:42:38Z","timestamp":1785332558200,"version":"3.55.0"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This study has been supported by the Recep Tayyip Erdo\u011fan University Development Foundation","award":["02025008011225"],"award-info":[{"award-number":["02025008011225"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Interest in biomarkers reflecting the inflammatory nature of Hodgkin lymphoma (HL) is increasing. This study aimed to evaluate the prognostic significance of the Systemic Inflammation Response Index (SIRI) in patients with HL. Materials and Methods: In this study, 105 patients diagnosed with classical HL at the Hematology Clinic of Recep Tayyip Erdo\u011fan University Faculty of Medicine between January 2015 and April 2025 were retrospectively evaluated. Patients were divided into 2 groups according to the SIRI cut-off value. Results: A high SIRI (\u22653.78) was significantly associated with advanced disease stage, poor performance status, higher IPS-7 and IPS-3 scores, non-response or partial response to treatment, relapse, and increased mortality. A positive correlation was found between SIRI and IPS 7 scores (p &lt; 0.001, rho = 0.355). In the univariate analysis for progression-free survival (PFS), hemoglobin, IPS 7 score, and SIRI were identified as prognostic factors; in the multivariate analysis, high SIRI was identified as an independent prognostic factor (p = 0.033). In the univariate analysis for overall survival (OS), age, hemoglobin, albumin, lymphocyte count, IPS 7 score, and SIRI were identified as prognostic factors; and, in the multivariate analysis, age over 45 and high SIRI were identified as independent prognostic factors (p = 0.016, p = 0.012). In the survival analysis, high SIRI levels were associated with shorter PFS and OS (p = 0.001, p &lt; 0.001). Additionally, PFS and OS durations were shorter in patients with high IPS 7 scores (p &lt; 0.001, p &lt; 0.001). Conclusions: A high SIRI prior to treatment was identified as an independent prognostic factor in HL patients and was associated with shorter PFS and OS. This index may help identify high-risk patients and assist clinicians in their decision-making processes by enabling individualized risk assessment.<\/jats:p>","DOI":"10.3390\/medicina62020264","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:27:11Z","timestamp":1769509631000},"page":"264","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Significance of the Systemic Inflammation Response Index (SIRI) in Patients with Hodgkin Lymphoma"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-0514","authenticated-orcid":false,"given":"Kadir","family":"Ilkkilic","sequence":"first","affiliation":[{"name":"Department of Hematology, School of Medicine, Recep Tayyip Erdogan University, Rize 53200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayram","family":"Sen","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Training and Research Hospital, Recep Tayyip Erdogan University, Rize 53200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/annonc\/mdy080","article-title":"ESMO Guidelines Committee. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","article-title":"Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant","volume":"54","author":"Arai","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"ECHELON-1 Study Group. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial","volume":"41","author":"Meissner","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.13634","article-title":"Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era","volume":"171","author":"Diefenbach","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.4103\/0366-6999.194661","article-title":"Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era","volume":"129","author":"Wang","year":"2016","journal-title":"Chin. Med. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1080\/10428194.2018.1540044","article-title":"Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas","volume":"60","author":"Biccler","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Triumbari, E.K.A., Morland, D., Cuccaro, A., Maiolo, E., Hohaus, S., and Annunziata, S. (2022). Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment. Diagnostics, 12.","DOI":"10.3390\/diagnostics12102325"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/ajco.13770","article-title":"A new prognostic model including platelet\/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma","volume":"18","author":"Tao","year":"2022","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","article-title":"Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma","volume":"31","author":"Scott","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1158\/1078-0432.CCR-19-2356","article-title":"A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients","volume":"26","author":"Luminari","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_14","first-page":"100","article-title":"The derived neutrophil-lymphocyte ratio and the neutrophil-lymphocyte ratio are related to poor prognosis in Hodgkin lymphoma patients","volume":"11","author":"Shen","year":"2021","journal-title":"Am. J. Blood Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3109\/10428194.2015.1110745","article-title":"Prognostic value of lymphocyte\/monocyte ratio in advanced Hodgkin lymphoma: Correlation with International Prognostic Score and tumor associated macrophages","volume":"57","author":"Jakovic","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00277-018-3276-y","article-title":"Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy","volume":"97","author":"Romano","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12967-019-1782-x","article-title":"Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer","volume":"17","author":"Zhang","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kim, M.R., Kim, A.S., Choi, H.I., Jung, J.H., Park, J.Y., and Ko, H.J. (2020). Inflammatory markers for predicting overall survival in gastric cancer patients: A systematic review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236445"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.2147\/CMAR.S193397","article-title":"Prognostic significance of peripheral blood absolute lymphocyte count and derived neutrophil to lymphocyte ratio in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2217\/bmm-2019-0303","article-title":"Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma","volume":"13","author":"Mirili","year":"2019","journal-title":"Biomark. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9570","DOI":"10.1002\/cam4.5733","article-title":"Prognosis and complications of patients with primary gastrointestinal diffuse large B-cell lymphoma: Development and validation of the systemic inflammation response index-covered score","volume":"12","author":"Chu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_23","first-page":"1350","article-title":"Effects of Prognostic Nutritional Index and Systemic Inflammatory Response Index on Short-Term Efficacy and Prognosis in Patients with Peripheral T-Cell Lymphoma","volume":"33","author":"Huang","year":"2025","journal-title":"J. Exp. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11060-024-04692-5","article-title":"Pre-treatment systemic inflammation response index and systemic immune inflammation in patients with primary central nerve system lymphoma as a useful prognostic indicator","volume":"168","author":"Matsuda","year":"2024","journal-title":"J. Neurooncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2147\/CMAR.S287897","article-title":"Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs","volume":"13","author":"Jiang","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2147\/CMAR.S235519","article-title":"Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator","volume":"12","author":"Chen","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.seminhematol.2016.05.007","article-title":"Hodgkin lymphoma: Pathology and biology","volume":"53","author":"Mathas","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.25122\/jml-2023-0019","article-title":"Assessment of tumor microenvironment expression and clinical significance of immune inhibitory molecule CTLA-4, ligand B7-1, and tumor-infiltrating regulatory cells in Hodgkin lymphoma","volume":"16","author":"Verma","year":"2023","journal-title":"J. Med. Life"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_30","unstructured":"National Comprehensive Cancer Network (2024). Hodgkin lymphoma. NCCN Clinical Practice Guidelines in Oncology, National Comprehensive Cancer Network."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.seminhematol.2016.05.002","article-title":"Hodgkin lymphoma in the elderly, pregnant, and HIV-infected","volume":"53","author":"Bachanova","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2010-08-302604","article-title":"Progress in Hodgkin lymphoma: A population-based study on patients diagnosed in Sweden from 1973\u20132009","volume":"119","author":"Halthur","year":"2012","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Gao, J., Chen, Y., Wu, P., Wang, F., Tao, H., Shen, Q., Wang, S., Gong, S., Zhang, X., and Zhou, Z. (2021). Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: A populated-based competing risk analysis. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08683-x"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"Fuchs","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: A comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hon.2830","article-title":"Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland","volume":"39","author":"Moccia","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International Prognostic Score in advanced-stage Hodgkin\u2019s lymphoma: Altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Duminuco, A., Del Fabro, V., Santuccio, G., Chiarenza, A., Caruso, A.L., Figuera, A., Motta, G., Fiumara, P.F., Petronaci, A., and Palumbo, F. (2025). Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life Study. Eur. J. Haematol.","DOI":"10.1111\/ejh.70066"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.22.02473","article-title":"The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium","volume":"41","author":"Rodday","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/0008-5472.CAN-15-0125","article-title":"Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth","volume":"75","author":"Ma","year":"2015","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.oraloncology.2013.12.009","article-title":"The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma","volume":"50","author":"Clatot","year":"2014","journal-title":"Oral. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrc1949","article-title":"Cysteine cathepsins: Multifunctional enzymes in cancer","volume":"6","author":"Mohamed","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages as major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Durgeau, A., Virk, Y., Corgnac, S., and Mami-Chouaib, F. (2018). Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00014"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1007\/s11255-023-03724-9","article-title":"Validation and comparison of prognostic value of different preoperative systemic inflammation indices in non-metastatic renal cell carcinoma","volume":"55","author":"Tang","year":"2023","journal-title":"Int. Urol. Nephrol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/264\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:47:11Z","timestamp":1769510831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["medicina62020264"],"URL":"https:\/\/doi.org\/10.3390\/medicina62020264","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}